Search
Displaying 111–120 of 624 for “retinal diseases”
-
Research News
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
Career Development Program (CDA)
Objective/Goal: The goal of this Program is to facilitate advances in laboratory and clinical research, to elucidate the mechanisms for the etiology and pathogenesis of retinal degenerative diseases and to develop innovative strategies to prevent, treat and cure these diseases. This program supports up to five junior-level faculty for five (5) years. $75,000/year
-
Researchers Find Mutation as Frequent Cause of RP in American Hispanics
Research NewsThe discovery can help genetic experts diagnose more patients with adRP, and it gives researchers a target for developing potential therapies.
-
Research News
Research has suggested that DHA in your diet is good for preventing and treating cardiovascular diseases, neurological conditions, depression and a slew of other conditions and maladies, including those that affect the retina.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
.png)
